Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
ThromBio Pty. Ltd.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06813651CT.gov Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Arterial Occlusion
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tbo-309 (this asset) | ThromBio Pty. Ltd. | P2 | CCC · 53 |
| 3-N-BUTYLPHTHALIDE | The Second Hospital of Hebei Medical University | P4 | BB |
| Apixaban | Columbia University | P3 | B |
| Ropivacaine | University of Sao Paulo General Hospital | P3 | B |
| Tenecteplase | Beijing Tiantan Hospital | P3 | B |
| Fentanyl | University of Sao Paulo General Hospital | P3 | B |
| Warfarin | Columbia University | P3 | B |
| Alteplase | The First Affiliated Hospital with Nanjing Medical University | P3 | B |
| Aspirin | The Second Hospital of Anhui Medical University | N/A | D |
+1 more in the Arterial Occlusion cohort
Other indications for Tbo-309
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ischemic Stroke | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tbo-309 in Arterial Occlusion. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tbo-309-arterial-occlusion
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →